Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2019 | 404 | 2.320 |
Why?
|
| Melanoma | 6 | 2019 | 334 | 1.780 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 715 | 0.910 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 24 | 0.780 |
Why?
|
| Dermatologists | 2 | 2018 | 11 | 0.780 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 11 | 0.780 |
Why?
|
| Dielectric Spectroscopy | 2 | 2019 | 3 | 0.670 |
Why?
|
| Sunscreening Agents | 5 | 2019 | 21 | 0.660 |
Why?
|
| Self-Examination | 1 | 2018 | 4 | 0.630 |
Why?
|
| Sunburn | 1 | 2018 | 11 | 0.620 |
Why?
|
| Margins of Excision | 1 | 2018 | 23 | 0.600 |
Why?
|
| Electric Impedance | 1 | 2018 | 35 | 0.600 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 61 | 0.570 |
Why?
|
| Mohs Surgery | 1 | 2018 | 52 | 0.570 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 180 | 0.530 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 233 | 0.510 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 702 | 0.500 |
Why?
|
| Paget Disease, Extramammary | 1 | 2012 | 2 | 0.410 |
Why?
|
| Scrotum | 1 | 2012 | 4 | 0.410 |
Why?
|
| Chordoma | 1 | 2012 | 6 | 0.400 |
Why?
|
| Sacrum | 1 | 2012 | 22 | 0.400 |
Why?
|
| Exanthema | 1 | 2012 | 27 | 0.400 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 117 | 0.370 |
Why?
|
| Skin | 3 | 2022 | 356 | 0.270 |
Why?
|
| Humans | 19 | 2023 | 59422 | 0.250 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1027 | 0.240 |
Why?
|
| Agammaglobulinemia | 1 | 2023 | 8 | 0.220 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2023 | 9 | 0.210 |
Why?
|
| Dermatologic Agents | 1 | 2022 | 21 | 0.200 |
Why?
|
| Sebaceous Glands | 1 | 2022 | 6 | 0.200 |
Why?
|
| Hair Follicle | 1 | 2022 | 29 | 0.200 |
Why?
|
| Psoriasis | 1 | 2022 | 51 | 0.190 |
Why?
|
| Masks | 1 | 2021 | 20 | 0.190 |
Why?
|
| Sun Protection Factor | 2 | 2019 | 2 | 0.190 |
Why?
|
| Biological Products | 1 | 2022 | 94 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 2595 | 0.180 |
Why?
|
| United States | 5 | 2018 | 7515 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 213 | 0.170 |
Why?
|
| Aged | 7 | 2018 | 13334 | 0.160 |
Why?
|
| Skin Aging | 1 | 2019 | 11 | 0.160 |
Why?
|
| Marketing | 1 | 2019 | 18 | 0.160 |
Why?
|
| Consumer Behavior | 1 | 2019 | 35 | 0.160 |
Why?
|
| Patient Medication Knowledge | 1 | 2018 | 3 | 0.160 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2019 | 34 | 0.160 |
Why?
|
| Drug Labeling | 1 | 2018 | 27 | 0.160 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 68 | 0.160 |
Why?
|
| Physician Assistants | 1 | 2018 | 37 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 41 | 0.150 |
Why?
|
| Frozen Sections | 1 | 2018 | 10 | 0.150 |
Why?
|
| False Negative Reactions | 1 | 2018 | 40 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2018 | 74 | 0.150 |
Why?
|
| Health Personnel | 1 | 2021 | 342 | 0.150 |
Why?
|
| Dermatology | 1 | 2018 | 69 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 2018 | 115 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 141 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 196 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2018 | 74 | 0.140 |
Why?
|
| Regional Health Planning | 1 | 2016 | 11 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2016 | 23 | 0.140 |
Why?
|
| Patient Care Bundles | 1 | 2016 | 11 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2021 | 425 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 23 | 0.140 |
Why?
|
| Safety-net Providers | 1 | 2016 | 34 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 220 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2016 | 120 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1094 | 0.120 |
Why?
|
| Female | 7 | 2018 | 30883 | 0.120 |
Why?
|
| Male | 6 | 2018 | 27545 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1548 | 0.110 |
Why?
|
| Adolescent | 2 | 2022 | 5918 | 0.110 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 15 | 0.100 |
Why?
|
| Niacinamide | 1 | 2012 | 32 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 29 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 98 | 0.100 |
Why?
|
| Pyridines | 1 | 2012 | 98 | 0.100 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2011 | 10 | 0.090 |
Why?
|
| Awareness | 1 | 2011 | 73 | 0.090 |
Why?
|
| Self Concept | 1 | 2011 | 103 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2011 | 218 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 40 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 3577 | 0.080 |
Why?
|
| Middle Aged | 4 | 2018 | 16248 | 0.080 |
Why?
|
| Adult | 3 | 2018 | 15762 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 645 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 2473 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2011 | 476 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 1572 | 0.060 |
Why?
|
| Biological Factors | 1 | 2022 | 23 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2022 | 80 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2019 | 10 | 0.040 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 6 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 34 | 0.040 |
Why?
|
| Coffee | 1 | 2019 | 19 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 219 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 153 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 95 | 0.040 |
Why?
|
| Baths | 1 | 2018 | 7 | 0.040 |
Why?
|
| Aerosols | 1 | 2018 | 44 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2018 | 137 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 132 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 137 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 375 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 105 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 200 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 220 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 54 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 453 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2018 | 223 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 67 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 314 | 0.030 |
Why?
|
| Water | 1 | 2018 | 295 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 265 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 669 | 0.030 |
Why?
|
| Transcriptome | 1 | 2018 | 329 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 673 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 331 | 0.030 |
Why?
|
| Agnosia | 1 | 2011 | 4 | 0.020 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 22 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2011 | 44 | 0.020 |
Why?
|
| Problem Solving | 1 | 2011 | 30 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2011 | 65 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6000 | 0.020 |
Why?
|
| Exercise | 1 | 2018 | 917 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 319 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 340 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5011 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1053 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5170 | 0.020 |
Why?
|